Drug Profile
CJM 112
Alternative Names: CJM112Latest Information Update: 10 Jan 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Anti-inflammatories; Antiacnes; Antiasthmatics; Antineoplastics; Antipsoriatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa
- Phase I/II Plaque psoriasis
- No development reported Acne; Asthma; Multiple myeloma; Multiple sclerosis; Solid tumours
Most Recent Events
- 10 Jan 2023 No development reported - Phase-II for Acne in Netherlands (SC)
- 02 Jan 2023 No development reported - Phase-II for Acne in Germany, USA (SC)
- 02 Jan 2023 No development reported - Phase-II for Asthma (Adjunctive treatment) in Slovakia, Denmark, Germany, Belgium, USA, Israel, France, Argentina (SC)